To assess the improvement in sexual function and self-perceived quality of life using PROMs (Patient-Reported Outcomes) in patients treated for cervical cancer who undergo a multimodal intervention in the sexual sphere and lifestyle compared to those who undergo care within routine clinical practice.
Women of legal age.
Patients with primary cervical cancer stage FIGO I-III (initial or locally advanced) of squamous histology, adenocarcinoma or adenosquamous.
Patients treated for cancer with surgery and/or radiotherapy ± systemic treatment in the Gynaecological Oncology Units of hospitals in Spain.
Complete response after oncospecific treatment was obtained.
Patients under 18 years of age.
Pregnancy or breastfeeding.
Partial response after completion of oncospecific treatment.
Patients with premalignant pathology.
Parallel
Sex hormones and modulators of the genital system.
DrugTo assess the improvement in sexual function and self-perceived quality of life using PROMs (Patient-Reported Outcomes) in patients treated for cervical cancer who undergo a multimodal intervention in the sexual sphere and lifestyle.
To evaluate the improvement in sexual function and self-perceived quality of life using Patient-Reported Outcomes in patients treated for cervical cancer who undergo a multimodal intervention in the sexual sphere and lifestyle.
Global score on the Female Sexual Function Index (FSFI) form at the end of the first year after treatment. The values go from zero to five, or from 1 to 5. A higher score mean a better outcome.
To evaluate sexual function (using the Female Sexual Function Index (FSFI) questionnaire) in women treated for cervical cancer after completion of treatment and its evolution over one year.
Score on the Female Sexual Function Index (FSFI) form at diagnosis, after treatment (defined as baseline level: 1 month after surgery and 3 months after treatment with radiotherapy ± systemic treatment), at 6 and 12 months after treatment. The score in each of the sexual response domains that make up the FSFI (subjective desire and stimulus, lubrication, orgasm, satisfaction, and pain or discomfort) will also be evaluated individually. The Female Sexual Function Index values go from zero to 5 or from 1 to 5. The higher scores the better outcome.
To evaluate self-perceived quality of life questionnaires in women treated for cervical cancer after completing treatment and its evolution over one year.
Score on the quality of life forms at diagnosis, at baseline level(after treatment), at 6 months and 12 months after baseline level(after treatment). The score on each of the 5 functional scales (physical functioning, daily activities, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), the global health status scale and the 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhoea and economic impact) that make up the European Organisation for Research and treatment of Cancer(EORTC QLQ-30) will also be assessed individually. The first 28 questions got values which go from 1 to 4 and the lower score the better outcome. The other two last ones have values go from 1 to 7 and the higher scores the better outcome.
To detect the needs of the treated patients based on the Patient-Reported Outcome Measures(PROMs) questionnaires, that allow proposing improvement strategies that can increase their sexual health and quality of life.
Adherence to multimodal treatment in the intervention arm, defined as the percentage of patients in the intervention arm who have undergone each of the items included in the multimodal treatment. The items included in the multimodal treatment are the use of moisturizing creams vaginal and vulvar without hormones and topical vaginal estrogens with their dosage, the use of the personal massager staff, and access to the informative content about life habits.
To evaluate vaginal trophism more objectively using the Vaginal Health Index (VHI) in women with cervical cancer after completion of treatment and over the course of one year.
Number of adverse effects related with the use of treatments, assessing their number, severity and type (A - Augmented; B - Bizarre)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
